Loading
Isolated the first blood stem cells and discovered the 'don't eat me' signal CD47 on cancer cells.
Irving Weissman is Virginia and D.K. Ludwig Professor and Founding Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine, within the Stanford Cancer Institute. A stem cell biologist, he first purified haematopoietic stem cells, defined leukaemia stem cells and identified CD47 as a macrophage checkpoint, the don't eat me signal on cancer cells, leading to magrolimab and the innate checkpoint field. His papers include the Cell report that CD47 is upregulated on circulating haematopoietic stem cells and leukaemia cells to avoid phagocytosis and a PNAS study of the CD47-SIRPa interaction as a therapeutic target in solid tumours. His work bears on acute myeloid leukaemia and diffuse large B-cell lymphoma.
| Title | Journal | Year |
|---|---|---|
| CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis | Cell | 2009 |
| The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors | Proceedings of the National Academy of Sciences of the United States of America | 2012 |
| Reya 2001: stem cells, cancer and cancer stem cells | Nature | 2001 |
Shares Magrolimab, CD47, Acute myeloid leukaemia, Diffuse large B-cell lymphoma.
Shares Reya 2001: stem cells, cancer and cancer stem cells, Cancer stem cell theory and phenotypic plasticity.
Shares Cancer stem cell theory and phenotypic plasticity, Acute myeloid leukaemia.
Shares Magrolimab, Acute myeloid leukaemia.
Shares Magrolimab, CD47, Acute myeloid leukaemia, Diffuse large B-cell lymphoma.
Shares Reya 2001: stem cells, cancer and cancer stem cells, Cancer stem cell theory and phenotypic plasticity.
Shares Stanford Health Care / Stanford Cancer Institute, Diffuse large B-cell lymphoma.
Shares Magrolimab, CD47.